Insulin Degludec Linked to Reduced Rate of Hypoglycemia

Share this content:
Insulin Degludec Linked to Reduced Rate of Hypoglycemia
Insulin Degludec Linked to Reduced Rate of Hypoglycemia

THURSDAY, July 6, 2017 (HealthDay News) -- For patients with type 1 or type 2 diabetes, insulin degludec is associated with a reduced rate of hypoglycemic episodes compared with insulin glargine, according to two studies published in the July 4 issue of the Journal of the American Medical Association.

Wendy Lane, M.D., from Mountain Diabetes and Endocrine Center in Asheville, N.C., and colleagues randomized 501 adults with type 1 diabetes with at least one hypoglycemia risk factor to receive insulin degludec followed by insulin glargine or insulin glargine followed by insulin degludec for 32 weeks. The researchers found that the rates of overall symptomatic hypoglycemia were 2,200.9 and 2,462.7 per 100 person-years' exposure (PYE) in the insulin degludec and insulin glargine groups, respectively, during the maintenance period (rate ratio, 0.89; 95 percent confidence interval, 0.85 to 0.94; P < 0.001 for noninferiority; P < 0.001 for superiority).

Carol Wysham, M.D., from the University of Washington School of Medicine in Spokane, and colleagues randomized 721 patients with type 2 diabetes and at least one hypoglycemia risk factor to receive insulin degludec followed by insulin glargine (361 patients) or insulin glargine followed by insulin degludec (360 patients) for 32 weeks. The researchers found that the rates of overall symptomatic hypoglycemia for insulin degludec versus insulin glargine were 185.6 versus 265.4 episodes per 100 PYEs (rate ratio, 0.70; 95 percent confidence interval, 0.61 to 0.80; P < 0.001) during the maintenance period.

"Thirty-two weeks' treatment with insulin degludec versus insulin glargine U100 resulted in a reduced rate of overall symptomatic hypoglycemia," Wysham and colleagues write.

Several authors from both studies disclosed financial ties to pharmaceutical companies, including Novo Nordisk, which manufactures degludec and funded the studies.

Abstract/Full Text - Lane (subscription or payment may be required)
Abstract/Full Text - Wysham (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Zika Does Not Appear to Last in Semen As Long As Thought

Zika Does Not Appear to Last in Semen ...

More research is needed to better inform public health recommendations

Radioiodine Therapy for Thyroid Cancer Doesn't Up Stroke Risk

Radioiodine Therapy for Thyroid Cancer Doesn't Up Stroke ...

I-131 therapy group showed no significantly higher risk of ischemic or hemorrhagic stroke

Higher Odds of Infection With Reduced Kidney Function

Higher Odds of Infection With Reduced Kidney Function

Study finds excess community-acquired infections incidence in individuals with mild to severe CKD

is free, fast, and customized just for you!

Already a member?

Sign In Now »